HER2 Heterogeneity Is Associated with Poor Survival in HER2-Positive Breast Cancer

被引：30

作者：

Hosonaga, Mari ^{[1
]}

Arima, Yoshimi ^{[2
]}

Sampetrean, Oltea ^{[2
]}

Komura, Daisuke ^{[3
]}

Koya, Ikuko ^{[4
]}

Sasaki, Takashi ^{[5
]}

Sato, Eiichi ^{[6
]}

Okano, Hideyuki ^{[4
]}

Kudoh, Jun ^{[7
]}

Ishikawa, Shumpei ^{[3
]}

Saya, Hideyuki ^{[2
]}

Ishikawa, Takashi ^{[1
]}

机构：

[1] Tokyo Med Univ, Dept Breast Surg & Oncol, Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan

[2] Keio Univ, Inst Adv Med Res, Div Gene Regulat, Sch Med,Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan

[3] Tokyo Med & Dent Univ, Med Res Inst, Dept Genom Pathol, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138510, Japan

[4] Keio Univ, Dept Physiol, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan

[5] Keio Univ, Ctr Supercentenarian Med Res, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan

[6] Tokyo Med Univ, Inst Med Sci, Dept Pathol, Med Res Ctr,Shinjuku Ku, 6-7-1 Nishishinjuku, Tokyo 1600023, Japan

[7] Keio Univ, Lab Gene Med, Sch Med, Shinjuku Ku, 35 Shinanomachi, Tokyo 1608582, Japan

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2018年 / 19卷 / 08期

关键词：

HER2; heterogeneity; breast cancer; poor prognosis; caspase-1; GENE AMPLIFICATION; INTRATUMORAL HETEROGENEITY; CELLS; CARCINOMAS; EXPRESSION; CASPASE-1; EVOLUTION; IMPACT;

D O I：

10.3390/ijms19082158

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Intratumoral human epidermal growth factor receptor 2 (HER2) heterogeneity has been reported in 16-36% of HER2-positive breast cancer and its clinical impact is under discussion. We examined the biological effects of HER2-heterogeneity on mouse models and analyzed metastatic brains by RNA sequence analysis. A metastatic mouse model was developed using 231-Luc (triple negative cells) and 2 HER2-positive cell lines, namely, HER2-60 and HER2-90 which showed heterogeneous and monotonous HER2 expressions, respectively. Metastatic lesions developed in 3 weeks in all the mice injected with HER2-60 cells, and in 69% of the mice injected with HER2-90 and 87.5% of the mice injected with 231-Luc. The median survival days of mice injected with 231-Luc, HER2-60, and HER2-90 cells were 29 (n = 24), 24 (n = 22) and 30 (n = 13) days, respectively. RNA sequence analysis showed that CASP-1 and its related genes were significantly downregulated in metastatic brain tumors with HER2-60 cells. The low expression of caspase-1 could be a new prognostic biomarker for early relapse in HER2-positive breast cancer.

引用

页数：12

共 50 条

[41] Pertuzumab in HER2-positive breast cancer
Sendur, Mehmet A. N.
Aksoy, Sercan
Altundag, Kadri
CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (10) : 1709 - 1716
[42] Association between HER2 heterogeneity and clinical outcomes of HER2-positive gastric cancer patients treated with trastuzumab
Bang, Kyunghye
Cheon, Jaekyung
Park, Young Soo
Kim, Hyung-Don
Ryu, Min-Hee
Park, Yangsoon
Moon, Meesun
Lee, Hyungeun
Kang, Yoon-Koo
GASTRIC CANCER, 2022, 25 (04) : 794 - 803
[43] Dual HER2 blockade in adjuvant and neoadjuvant treatment of HER2-positive breast cancer: the role of pertuzumab
Duchnowska, Renata
ONCOLOGY IN CLINICAL PRACTICE, 2018, 14 (01): : 43 - 47
[44] Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours
Tovey, S. M.
Brown, S.
Doughty, J. C.
Mallon, E. A.
Cooke, T. G.
Edwards, J.
BRITISH JOURNAL OF CANCER, 2009, 100 (05) : 680 - 683
[45] HER2-positive gastric cancer identified by serum HER2: A case report
Saito, Mayuko
Kawakami, Yujiro
Yamashita, Kentaro
Nasuno, Hiroshi
Ishimine, Yu
Fukuda, Koichiro
Isshiki, Hiroyuki
Suzuki, Ryo
Arimura, Yoshiaki
Shinomura, Yasuhisa
ONCOLOGY LETTERS, 2016, 11 (06) : 3575 - 3578
[46] HER2 Gene Protein Assay Is Useful to Determine HER2 Status and Evaluate HER2 Heterogeneity in HER2 Equivocal Breast Cancer
Hou, Yanjun
Nitta, Hiroaki
Li, Zaibo
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2017, 147 (01) : 89 - 95
[47] Quantitative assessment of HER2 amplification in HER2-positive breast cancer: its association with clinical outcomes
Xuan, Qijia
Ji, Hongfei
Tao, Xuanchen
Xu, Yongpeng
Zhang, Qingyuan
BREAST CANCER RESEARCH AND TREATMENT, 2015, 150 (03) : 581 - 588
[48] Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations
Kourie, Hampig Raphael
Chaix, Marie
Gombos, Andrea
Aftimos, Phillippe
Awada, Ahmad
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (08) : 947 - 957
[49] Her2 positive breast cancer: practices
Campone, Mario
Berton-Rigaud, Dominique
Bourbouloux, Emmanuelle
Sophie, Sadot
Zanetti, Alain
Frenel, Jean-Sebastien
BULLETIN DU CANCER, 2011, 98 (02) : 154 - 163
[50] HER2 intratumoral heterogeneity analyses by concurrent HER2 gene and protein assessment for the prognosis of HER2 negative invasive breast cancer patients
Sasagu Kurozumi
Mary Padilla
Masafumi Kurosumi
Hiroshi Matsumoto
Kenichi Inoue
Jun Horiguchi
Izumi Takeyoshi
Tetsunari Oyama
Jim Ranger-Moore
D. Craig Allred
Eslie Dennis
Hiroaki Nitta
Breast Cancer Research and Treatment, 2016, 158 : 99 - 111

← 1 2 3 4 5 →